TxCell’s new and novel CAR-modified regulatory T-cell (CAR Treg) platform has developed rapidly since June with three key academic collaborations aimed at progressing a range of indications including an important one aimed at controlling transplant rejection. CAR Treg trials may start from 2018. The Ovasave Crohn’s Phase IIb will now start in 2018, formerly H216, with faster manufacturing. We expect a cash inflow in H216 of €7m with forecast cash of €3.5m at year end aft
28 Oct 2016
Increasing CAR Treg emphasis
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Increasing CAR Treg emphasis
Txcell (TXCL:EPA) | 0 0 -1.3% | Mkt Cap: 29.4m
- Published:
28 Oct 2016 -
Author:
Dr John Savin -
Pages:
9
TxCell’s new and novel CAR-modified regulatory T-cell (CAR Treg) platform has developed rapidly since June with three key academic collaborations aimed at progressing a range of indications including an important one aimed at controlling transplant rejection. CAR Treg trials may start from 2018. The Ovasave Crohn’s Phase IIb will now start in 2018, formerly H216, with faster manufacturing. We expect a cash inflow in H216 of €7m with forecast cash of €3.5m at year end aft